Intralesional immunotherapy for melanoma

Journal of Surgical Oncology

Volumn 109, Issue 4, 2014, Pages 320-326

  Hersey, Peter ^a,b   Gallagher, Stuart ^b  

^a MELANOMA INSTITUTE AUSTRALIA   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

GM CSF; immune responses; intralesional therapy; melanoma; oncolytic viruses

Indexed keywords

GM-CSF; IMMUNE RESPONSES; INTRALESIONAL THERAPY; MELANOMA; ONCOLYTIC VIRUSES;

ANIMALS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRALESIONAL; MELANOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84893937889     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23494     Document Type: Review

References (43)

1. Hodi FS, et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
2. Robert C, et al.: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
3. Eggermont AM, Kirkwood JM:, Re-evaluating the role of dacarbazine in metastatic melanoma: What have we learned in 30 years ? Eur J Cancer 2004; 40: 1825-1836.
4. Roenigk HH, Jr., et al.: Immunotherapy of malignant melanoma with vaccinia virus. Arch Dermatol 1974; 109: 668-673.
5. Belisario JC, Milton GW:, The experimental local therapy of cutaneous metastases of malignant melanoblastomas with cow pox vaccine or colcemid (demecolcine or omaine). Aust J Dermatol 1961; 6: 113-118.
6. Milton GW:, Some methods used in the management of metastatic malignant melanoma. Aust J Dermatol 1963; 7: 15-22.
7. Old LJ, Clarke DA, Benacerraf B:, Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature 1959; 184: 291-292.
8. Morton DL, et al.: BCG immunotherapy of malignant melanoma: Summary of a seven-year experience. Ann Surg 1974; 180: 635-643.
9. Storm FK, Sparks FC, Morton DL:, Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guerin and hyperthermic perfusion. Surg Gynecol Obstet 1979; 149: 17-21.
10. Mastrangelo MJ, et al.: Intralesional BCG in the treatment of metastatic malignant melanoma. Cancer 1976; 37: 684-692.
11. Mastrangelo MJ, et al.: Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases. Cancer 1975; 36: 1305-1308.
12. de la Monte SM, Hutchins GM:, Fatal disseminated bacillus Calmette-Guerin infection and arrested growth of cutaneous malignant melanoma following intralesional immunotherapy. Am J Dermatopathol 1986; 8: 331-335.
13. Agarwala SS, et al.: Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): A trial of the Eastern Oncology Group. Cancer 2004; 100: 1692-1698.
14. Dranoff G:, GM-CSF-secreting melanoma vaccines. Oncogene 2003; 22: 3188-3192.
15. Si Z, Hersey P, Coates AS:, Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res 1996; 6: 247-255.
16. von Wussow P, et al.: Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 1988; 61: 1071-1074.
17. Kubo H, et al.: Interferon-beta therapy for malignant melanoma: The dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells. Arch Dermatol Res 2008; 300: 297-301.
18. Singh AS, Radu CG, Ribas A:, PET imaging of the immune system: Immune monitoring at the whole body level. Q J Nucl Med Mol Imaging 2010; 54: 281-290.
19. McArthur GA, et al.: Marked, homogeneous, and early [18F] fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol 2012; 30: 1628-1634.
20. Wolchok JD, et al.: Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420.
21. Doukas J, Rolland A:, Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma. Cancer Gene Ther 2012; 19: 811-817.
22. Khong HT, Restifo NP:, Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002; 3: 999-1005.
23. Bedikian AY, et al.: A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res 2010; 20: 218-226.
24. Prestwich RJ, et al.: The case of oncolytic viruses versus the immune system: Waiting on the judgment of Solomon. Hum Gene Ther 2009; 20: 1119-1132.
25. Mullen JT, Tanabe KK:, Viral oncolysis. Oncologist 2002; 7: 106-119.
26. Breitbach CJ, et al.: Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res 2013; 73: 1265-1275.
27. Liu BL, et al.: ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003; 10: 292-303.
28. Senzer NN, et al.: Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27: 5763-5771.
29. Russell SJ, Peng KW, Bell JC:, Oncolytic virotherapy. Nat Biotechnol 2012; 30: 658-670.
30. Andtbacka RHI CF, Amatruda T, Senzer NN, et al.: OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol 2013; 31 (abstr LBA9008).
31. Shafren DR, et al.: Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin Cancer Res 2004; 10: 53-60.
32. Andtbacka RHI, Kaufman H, Daniels GA, et al.: CALM study: A phase II study of intratumoral coxsackievirus A21 in patients with stage IIIc and stage IV malignant melanoma. J Clin Oncol 2013; 31 (abstr TPS3128).
33. Flaherty KT, et al.: Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. N Engl J Med 2012; 367: 1694-1703.
34. Chapman PB, et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
35. Hamid O, et al.: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-144.
36. Topalian SL, et al.: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
37. Wolchok JD, et al.: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-133.
38. Koya RC, et al.: BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res 2012; 72: 3928-3937.
39. Frederick DT, et al.: BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013; 19: 1225-1231.
40. Knight DA, et al.: Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 2013; 123: 1371-1381.
41. Wilmott JS, et al.: Selective BRAF inhibitors induce marked T cell infiltration into human metastatic melanoma. Clin Cancer Res 2012; 18: 1386-1394.
42. Jiang X, et al.: The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res 2013; 19: 598-609.
43. Testori A, et al.: Local and intralesional therapy of in-transit melanoma metastases. J Surg Oncol 2011; 104: 391-396.